RITUXIMAB-INDUCED SEVERE ACUTE THROMBOCYTOPENIA IN A PATIENT WITH SPLENIC MARGINAL ZONE LYMPHOMA
Objective: Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological. Rituximab may cause thrombocytopenia in the long term after administration. Rare cas...
Main Authors: | Taha Ulutan Kars, Zahit Furkan Yorgancı, Osman Yaşkıran, Atakan Tekinalp |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-10-01
|
Series: | Hematology, Transfusion and Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137922013797 |
Similar Items
-
Splenic marginal zone lymphoma in Sweden 2000–2020: Increasing rituximab use and better survival in the elderly
by: Henna‐Riikka Junlén, et al.
Published: (2023-08-01) -
Might periostin serve as a marker of bone marrow involvement in patients with diffuse large B-cell lymphoma?
by: Tekinalp Atakan, et al.
Published: (2022-10-01) -
PB2291: EFFICACY OF SPLENECTOMY IN SPLENIC MARGINAL ZONE LYMPHOMA
by: Yuriy Yevstakhevych, et al.
Published: (2023-08-01) -
New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas
by: Marie Donzel, et al.
Published: (2021-09-01) -
Recurrent autoimmune hemolytic anemia in splenic marginal zone lymphoma
by: Oreoluwa Oladiran, et al.
Published: (2018-07-01)